Purpose: To evaluate the baseline visual and optical coherence tomography (OCT) predictive factors on outcomes after intravitreal bevacizumab treatment of subfoveal neovascular age-related macular degeneration (AMD).
Methods: Retrospective analysis of 73 eyes treated with intravitreal bevacizumab for subfoveal neovascular AMD was performed. Change in best corrected Snellen visual acuity (BCVA) and central retinal thickness (CRT) on OCT were the primary outcomes. Automated and manual measurements were made for all OCT characteristics.
Results: Seventy-three (100%) and 58 (79.5%) eyes were followed for 3 and 6 months, respectively. Mean BCVA improved from 20/177 to 20/160 (p=0.03) at 3 months and to 20/143 (p=0.04) at 6 months. Mean CRT decreased 93μm (p<0.0001) and 105μm (p<0.0001) at 3 and 6 months, respectively. Baseline BCVA worse than 20/100 was associated with greater visual improvement (p≤0.04). Eyes with baseline CRT greater than 400μm experienced greater mean CRT reduction (p<0.05). Treatment-naïve patients had greater mean CRT reduction than those previously treated with any modality (p<0.05).
Conclusions: Baseline BCVA and CRT positively influence mean visual and CRT improvement, respectively after intravitreal bevacizumab in wet AMD. Any prior treatment predicted less CRT reduction.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.